Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT00003816
First received: November 1, 1999
Last updated: October 8, 2013
Last verified: October 2013
  Purpose

RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor stem cell helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known which combination chemotherapy regimen is most effective when given before a donor stem cell transplant in treating aplastic anemia or hematologic cancer.

PURPOSE: This phase II/III trial is studying different combination chemotherapy regimens to compare how well they work when given before donor stem cell transplant in treating patients with aplastic anemia or hematologic cancer.


Condition Intervention Phase
Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Nonmalignant Neoplasm
Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific
Biological: anti-thymocyte globulin
Drug: busulfan
Drug: carboplatin
Drug: cyclophosphamide
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Drug: thiotepa
Radiation: total-body irradiation
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia

Resource links provided by NLM:

Genetic and Rare Diseases Information Center resources: Leukemia, Myeloid Chronic Myeloid Leukemia Myelodysplastic Syndromes Lymphosarcoma Lymphoma, Small Cleaved-cell, Diffuse Acute Lymphoblastic Leukemia Aplastic Anemia Chronic Myeloproliferative Disorders Waldenstrom Macroglobulinemia Acute Myelocytic Leukemia Acute Non Lymphoblastic Leukemia Myelodysplastic/myeloproliferative Disease Acute Myeloid Leukemia, Adult Follicular Lymphoma B-cell Lymphomas Myelofibrosis Burkitt Lymphoma Lymphoma, Large-cell Lymphoma, Large-cell, Immunoblastic Plasmablastic Lymphoma Lymphoblastic Lymphoma Small Non-cleaved Cell Lymphoma Anaplastic Large Cell Lymphoma Chronic Lymphocytic Leukemia Leukemia, B-cell, Chronic Chronic Myelomonocytic Leukemia Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Mantle Cell Lymphoma Cutaneous T-cell Lymphoma Polycythemia Vera Essential Thrombocythemia Leukemia, T-cell, Chronic Angioimmunoblastic T-cell Lymphoma Angioimmunoblastic Lymphadenopathy With Dysproteinemia Mycosis Fungoides Sezary Syndrome Large Granular Lymphocyte Leukemia
U.S. FDA Resources

Further study details as provided by Roswell Park Cancer Institute:

Primary Outcome Measures:
  • Activity of allogeneic stem cell transplant [ Time Frame: day 100 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Influence of donor histocompatibility on outcome [ Time Frame: Day 100 ] [ Designated as safety issue: No ]

Enrollment: 362
Study Start Date: October 1998
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Regimen 1
Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
Drug: busulfan
Given IV
Drug: cyclophosphamide
Given IV
Experimental: Regimen 2
Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -3.
Biological: anti-thymocyte globulin
Given IV
Drug: cyclophosphamide
Given IV
Experimental: Regimen 3
Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1.
Drug: cyclophosphamide
Given IV
Radiation: total-body irradiation
Given twice daily for 3 days
Experimental: Regimen 4
Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2.
Drug: fludarabine phosphate
Given IV
Drug: melphalan
Given IV
Experimental: Regimen 5
Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.
Drug: cyclophosphamide
Given IV
Drug: etoposide
Given IV
Radiation: total-body irradiation
Given twice daily for 3 days
Experimental: Regimen 6
Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4.
Drug: carboplatin
Given IV
Drug: cyclophosphamide
Given IV
Drug: thiotepa
Given IV
Experimental: Regimen 7
Patients receive fludarabine IV over 30 minutes on days -5 to -1 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -2.
Biological: anti-thymocyte globulin
Given IV
Drug: fludarabine phosphate
Given IV
Experimental: Regimen 8
Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1.
Biological: anti-thymocyte globulin
Given IV
Drug: cyclophosphamide
Given IV
Radiation: total-body irradiation
Given twice daily for 3 days
Experimental: Regimen 9
Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
Biological: anti-thymocyte globulin
Given IV
Drug: busulfan
Given IV
Drug: cyclophosphamide
Given IV

Detailed Description:

OBJECTIVES:

  • Compare the morbidity, mortality, and overall outcome of patients with severe aplastic anemia or hematologic malignancy treated with standard vs novel conditioning regimens followed by allogeneic stem cell transplantation.
  • Examine the influence of donor histocompatibility on outcome by comparing matched/related, mismatched/related (with or without T-cell depletion), and matched/unrelated transplants with stratification for type of preparative regimen.
  • Ensure that patients with uncommon diagnoses will be treated in a uniform fashion with the best therapy available.

OUTLINE: Patients are stratified according to risk of relapse (standard-risk: acute leukemia in first complete remission, chronic myelogenous leukemia in first chronic phase, lymphoma in sensitive first relapse or second remission, primary or untreated myelodysplastic syndromes, or untreated severe aplastic anemia vs high-risk: all others).

Patients are assigned to one of the following conditioning regimens based on diagnosis, risk of relapse, and donor relatedness:

  • Regimen 1: Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
  • Regimen 2: Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -3.
  • Regimen 3: Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1.
  • Regimen 4: Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2.
  • Regimen 5: Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.
  • Regimen 6: Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4.
  • Regimen 7: Patients receive fludarabine IV over 30 minutes on days -5 to -1 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -2.
  • Regimen 8: Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1.
  • Regimen 9: Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.

All patients then receive donor stem cell infusions on day 0. Some patients may undergo involved-field radiotherapy 4-8 weeks after transplant.

Patients are followed periodically post-transplant.

PROJECTED ACCRUAL: At least 405 patients will be accrued for this study within 5 years.

  Eligibility

Ages Eligible for Study:   4 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of one of the following:

    • Severe aplastic anemia as defined by either of the following:

      • Marrow cellularity (< 25% [or 25-50% cellularity with < 30% of remaining cells hematopoietic in origin])
      • At least 2 of the following abnormal peripheral blood counts:

        • Reticulocyte count < 1% (corrected for hematocrit)
        • Platelet count < 20,000/mm^3
        • Neutrophil count < 500/mm^3
    • Histologically confirmed hematologic malignancy, including any of the following:

      • Acute leukemia

        • Resistant or recurrent disease after combination chemotherapy with at least one standard regimen OR in first remission and at high risk of relapse
        • Acute myeloid leukemia (AML) (antecedent myelodysplastic syndromes [MDS], secondary AML, or high-risk cytogenetic abnormalities)
        • Acute lymphoblastic leukemia (ALL) (high-risk cytogenetic abnormalities)
      • Chronic myeloid leukemia (CML)

        • Chronic phase, accelerated phase, or blast phase
      • Myeloproliferative disorders or MDS, including any of the following:

        • Myelofibrosis
        • Polycythemia vera*
        • Essential thrombocythemia*
        • Refractory anemia
        • Refractory anemia with excess blasts
        • Refractory anemia with excess blasts in transformation
        • Chronic myelomonocytic leukemia NOTE: * Only if transformed to AML or MDS
      • Lymphoproliferative disease

        • Recurrent or persistent, symptomatic disease after first-line chemotherapy, including any of the following:

          • Chronic lymphocytic leukemia (CLL) (≥ 20% marrow involvement)
          • Waldenstrom macroglobulinemia
          • Low-grade non-Hodgkin lymphoma
      • Intermediate or high-grade non-Hodgkin lymphoma, meeting 1 of the following criteria:

        • Resistant or recurrent disease after combination chemotherapy with one standard regimen
        • Lymphoblastic lymphoma or small noncleaved cell lymphoma in first remission and at high risk of relapse
        • CNS disease
        • Bone marrow disease and LDH greater than 300
    • Solid tumor that would otherwise be treated on RPCI-DS-9115 (or equivalent autologous stem transplant protocol) AND has a syngeneic donor
  • Autologous bone marrow transplant not possible (or desirable) due to 1 of the following:

    • History of marrow tumor
    • Inadequate marrow dose
    • Abnormal marrow histology or function prior to storage
    • Thrombocytopenia or leukopenia
    • Marrow cellularity < 20%
  • Histocompatible donor identified

    • Well-matched donor, as defined by 1 of the following:

      • Family member matched for 5 or 6 HLA specificities (A, B, DR)*
      • Unrelated donor meeting compatibility criteria of the National Marrow Donor Program (matched for HLA A, B, and DRB1 antigens)*
      • Identical twin sibling
    • If a compatible cord blood donor is identified and there is no suitable unrelated donor available, patient may receive cord blood transplant NOTE: *Patients ≤ 25 years of age may be singly mismatched at the A or B loci

NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

Age:

  • 4 to 70

Performance status:

  • Zubrod 0-2 OR
  • Karnofsky 70-100%

Life expectancy:

  • Not specified

Hematopoietic:

  • See Disease Characteristics

Hepatic:

  • Bilirubin < 3 times normal (unless due to disease)
  • Alkaline phosphatase < 3 times normal (unless due to disease)
  • SGOT < 3 times normal (unless due to disease)
  • Hepatitis B surface antigen negative
  • No severe hepatic disease that would preclude study participation

Renal:

  • Creatinine normal
  • Creatinine clearance ≥ 50 mL/min
  • No severe renal disease that would preclude study participation

Cardiovascular:

  • Cardiac ventricular ejection fraction ≥ 50% by MUGA or echocardiogram
  • No uncontrolled or severe cardiovascular disease (e.g., myocardial infarction, congestive heart failure, symptomatic angina, life threatening arrhythmia, or hypertension within the past 6 months)

Pulmonary:

  • DLCO or DLVA ≥ 50% predicted (corrected for hemoglobin or alveolar ventilation)

Other:

  • No serious concurrent medical or psychiatric illness
  • No other serious organ dysfunction (unless due to underlying disease), including the following:

    • Uncontrolled bacterial, viral, or fungal infection
    • Uncontrolled peptic ulcer disease
    • Uncontrolled diabetes mellitus
  • HIV negative
  • Cytomegalovirus status known
  • Not pregnant

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • See Disease Characteristics
  • Pretransplant cytoreductive chemotherapy allowed for patients with relapsed or refractory disease

Endocrine therapy:

  • Not specified

Radiotherapy:

  • Not eligible for total-body irradiation if prior radiotherapy exceeded the following limits:

    • Mediastinum: 3,600 cGy
    • Heart: 3,600 cGy
    • Whole lungs: 1,200 cGy
    • Small bowel: 3,600 cGy
    • Kidneys: 1,200 cGy
    • Whole liver: 1,600 cGy
    • Cranial spinal: 3,600 cGy
    • Brain: 4,000 cGy
    • Retina: 4,000 cGy

Surgery:

  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00003816

Locations
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263-0001
Sponsors and Collaborators
Roswell Park Cancer Institute
Investigators
Study Chair: Philip L. McCarthy, MD Roswell Park Cancer Institute
  More Information

Additional Information:
No publications provided

Responsible Party: Roswell Park Cancer Institute
ClinicalTrials.gov Identifier: NCT00003816     History of Changes
Other Study ID Numbers: CDR0000066968, RP 98-15
Study First Received: November 1, 1999
Last Updated: October 8, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Roswell Park Cancer Institute:
recurrent childhood acute lymphoblastic leukemia
recurrent cutaneous T-cell non-Hodgkin lymphoma
Burkitt lymphoma
Waldenstrom macroglobulinemia
recurrent childhood lymphoblastic lymphoma
recurrent childhood acute myeloid leukemia
recurrent adult acute myeloid leukemia
recurrent adult acute lymphoblastic leukemia
relapsing chronic myelogenous leukemia
refractory chronic lymphocytic leukemia
chronic phase chronic myelogenous leukemia
accelerated phase chronic myelogenous leukemia
blastic phase chronic myelogenous leukemia
adult acute myeloid leukemia in remission
adult acute lymphoblastic leukemia in remission
childhood acute myeloid leukemia in remission
childhood acute lymphoblastic leukemia in remission
polycythemia vera
essential thrombocythemia
refractory anemia
refractory anemia with excess blasts
refractory anemia with excess blasts in transformation
chronic myelomonocytic leukemia
T-cell large granular lymphocyte leukemia
acute undifferentiated leukemia
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
recurrent grade 3 follicular lymphoma
recurrent adult diffuse small cleaved cell lymphoma
recurrent adult diffuse mixed cell lymphoma

Additional relevant MeSH terms:
Anemia
Anemia, Aplastic
Neoplasms
Leukemia
Lymphoma
Myelodysplastic Syndromes
Preleukemia
Myeloproliferative Disorders
Myelodysplastic-Myeloproliferative Diseases
Hematologic Diseases
Bone Marrow Diseases
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Precancerous Conditions
Antilymphocyte Serum
Busulfan
Cyclophosphamide
Melphalan
Thiotepa
Fludarabine phosphate
Etoposide phosphate
Fludarabine
Etoposide
Carboplatin
Vidarabine
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 28, 2014